Monotherapy for postmenopausal women w/ oestrogen receptor +ve, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antiestrogen therapy, or disease progression on therapy w/ antiestrogen. In combination w/ palbociclib for hormone receptor (HR) +ve , human epidermal growth factor receptor 2 (HER2) -ve locally advanced or metastatic breast cancer in woman w/ prior endocrine therapy. In combination w/ palbociclib & LH releasing hormone (LHRH) agonist in pre- or perimenopausal women.
Administer as 2 consecutive 5 mL inj by slow IM inj (1-2 min/inj), 1 in each buttock. Adult females (including the elderly) 500 mg at 1 mth interval w/ additional 500 mg dose given 2 wk after the initial dose.
Bleeding diastheses, thrombocytopenia, anticoagulant intake. Thromboembolic events in women w/ advanced breast cancer. Caution in administering at dorsogluteal inj site. Risk of osteoporosis. Critical visceral disease. May interfere w/ Ab based-oestradiol assays & may result in falsely increased oestradiol levels. Mild to moderate hepatic impairment. Severe renal impairment (CrCl <30 mL/min). May influence ability to drive or use machines. Patients of childbearing potential should use effective contraception during treatment & for 2 yr after the last dose. Contraindicated in pregnancy & lactation. Childn & adolescents.
Sign Out
